PROTEOMEDIX

Proteomedix was founded in 2010 as a spin-off company of ETH Zurich to bring together the exceptional and specific expertise of a multi-disciplinary group of the world's leading scientists and clinicians. As a medical need-oriented organization with a strong focus on research and development, it relies on a powerful network of clinicians, IVD experts, pharmacists and marketers. Proteomedix is located at the Bio-Technopark in Zurich, Switzerland... After its maiden product, the Proclarix test for improving prostate cancer diagnosis, Proteomedix is now developing additional products for prostate cancer prognosis and patient selection to enable precision medicine... Today, the initial step to diagnose prostate cancer is by testing PSA together with a digital rectal examination (DRE). The PSA test is a well-established prostate-specific marker that measures the concentration of PSA molecules (Prostate-Specific Antigen) in a blood sample. A high level of PSA can be a sign of prostate..

Also known as: Proteomedix AG

Primary location: Schlieren Switzerland